耐受性
医学
伊布替尼
布鲁顿酪氨酸激酶
耐火材料(行星科学)
子群分析
临床研究阶段
肿瘤科
内科学
不利影响
临床试验
白血病
慢性淋巴细胞白血病
荟萃分析
受体
酪氨酸激酶
物理
天体生物学
作者
William G. Wierda,Nirav Niranjan Shah,Chan Yoon Cheah,David John Lewis,Marc Steven Hoffmann,Catherine Callaghan Coombs,Nicole Lamanna,Shuo Ma,Deepa Jagadeesh,Talha Munir,Yucai Wang,Toby Andrew Eyre,Joanna Meehan Rhodes,Matthew Stuart McKinney,Ewa Lech‐Marańda,Constantine Si Lun Tam,Wojciech J. Jurczak,Koji Izutsu,Alvaro Jose Alencar,Manish R Patel
标识
DOI:10.1016/s2352-3026(24)00172-8
摘要
Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated with a poor prognosis. Pirtobrutinib has shown promising efficacy and tolerability in patients with relapsed or refractory B-cell malignancies, including those who progress on covalent Bruton tyrosine kinase (BTK) inhibitors. This study aims to report the safety and activity of pirtobrutinib monotherapy in a subgroup of patients with Richter transformation from the multicentre, open-label, phase 1/2 BRUIN study.
科研通智能强力驱动
Strongly Powered by AbleSci AI